Co-Authors
This is a "connection" page, showing publications co-authored by MICHELE REDELL and ALEXANDRA STEVENS.
Connection Strength
4.154
-
Addressing a Pre-Clinical Pipeline Gap: Development of the Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Program at Texas Children's Hospital at Baylor College of Medicine. Biomedicines. 2024 Feb 08; 12(2).
Score: 0.987
-
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated. Cancers (Basel). 2023 Feb 20; 15(4).
Score: 0.923
-
IL-10 and TNFa are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report. Pediatr Hematol Oncol. 2023 Mar; 40(2):147-158.
Score: 0.885
-
Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions. Children (Basel). 2021 Aug 12; 8(8).
Score: 0.830
-
Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia. Clin Transl Oncol. 2021 Oct; 23(10):2141-2154.
Score: 0.204
-
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv. 2019 12 23; 3(24):4215-4227.
Score: 0.185
-
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers (Basel). 2023 Mar 26; 15(7).
Score: 0.058
-
Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
Score: 0.049
-
Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity. Angew Chem Int Ed Engl. 2015 Oct 26; 54(44):13085-9.
Score: 0.034